Company profile: Lilly
1.1 - Company Overview
Company description
- Provider of medicines for diabetes, cancer, immunology, and other major health areas, including insulin products with affordability initiatives ($35 or less/month); Efsitora for type 2 diabetes via autoinjector; EBGLYSS for moderate-to-severe atopic dermatitis; Jaypirca for relapsed/refractory MCL and CLL/SLL; Zepbound (tirzepatide) for obesity; Verzenio for HR+, HER2- early breast cancer.
Products and services
- Zepbound (tirzepatide): A medication for obesity in single-dose vials, delivering a cost-effective option compared to other incretin medicines for patients
- Efsitora: A medication used in the treatment of type 2 diabetes, administered via autoinjector, helping patients achieve A1C reduction
- EBGLYSS: A biologic treatment for moderate-to-severe atopic dermatitis, providing skin clearance and itch relief for patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lilly
Confo Therapeutics
HQ: Belgium
Website
- Description: Provider of GPCR-focused drug discovery solutions leveraging proprietary Confo® Technology and conformationally selective VHH ConfoBodies® to stabilize GPCRs in active, disease-relevant states. Offerings include ConfoScreen®, ConfoSensor®, and ConfoStructure™ for screening, biosensing, and structure-based design, and MegaBody™ for high-resolution cryo-EM, enabling novel medicine discovery and internal programs addressing unmet medical need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Confo Therapeutics company profile →
GSK
HQ: United Kingdom
Website
- Description: Provider of pharmaceutical medicines, vaccines, and consumer healthcare products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GSK company profile →
LP Pharmaceuticals
HQ: China
Website
- Description: Provider of pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LP Pharmaceuticals company profile →
Stada
HQ: Germany
Website
- Description: Provider of pharmaceuticals and non-prescription consumer health products, operating on three pillars: OTC consumer healthcare, generics, and specialty pharmaceuticals. Sells products in over 120 countries, including acetaminophen, lactulose, Grippostad-C, Vitaprost, Cardiomagnyl, Xefocam Rapid, Aqualor, Edarbi, and Levomekol.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stada company profile →
Sagimet Biosciences
HQ: United States
Website
- Description: Provider of novel therapeutics targeting FASN, including Denifanstat, an oral, once-daily selective FASN inhibitor in development for MASH, acne, and certain cancers, and TVB-3567, a pipeline FASN inhibitor planned for U.S. clinical development for acne.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sagimet Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lilly
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lilly
2.2 - Growth funds investing in similar companies to Lilly
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lilly
4.2 - Public trading comparable groups for Lilly
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →